United States securities and exchange commission logo

                            June 21, 2021

       Timothy Noyes
       Chief Executive Officer
       Aerovate Therapeutics, Inc.
       200 Berkeley Street, Floor 18
       Boston, MA 02116

                                                        Re: Aerovate
Therapeutics, Inc.
Statement on Form S-1
                                                            Filed June 9, 2021
                                                            File No. 333-256949

       Dear Mr. Noyes:

              We have reviewed your registration statement and have the
following comments. In
       some of our comments, we may ask you to provide us with information so
we may better
       understand your disclosure.

              Please respond to this letter by amending your registration
statement and providing the
       requested information. If you do not believe our comments apply to your
facts and
       circumstances or do not believe an amendment is appropriate, please tell
us why in your

              After reviewing any amendment to your registration statement and
the information you
       provide in response to these comments, we may have additional comments.
Unless we note
       otherwise, our references to prior comments are to comments in our June
2, 2021 letter.

       Registration Statement on Form S-1 Filed June 9, 2021

       Prospectus Summary
       Overview, page 1

   1.                                                   We note your response
to comment 3. Please revise your disclosure to describe the
                                                        serious adverse events
that were observed during the Phase 3 trial conducted by Novartis.
               We remind you that the company and its management are
responsible for the accuracy
       and adequacy of their disclosures, notwithstanding any review, comments,
action or absence of
       action by the staff.
 Timothy Noyes
Aerovate Therapeutics, Inc.
June 21, 2021
Page 2

       Refer to Rules 460 and 461 regarding requests for acceleration. Please
allow adequate
time for us to review any amendment prior to the requested effective date of
the registration

       You may contact Michael Fay at 202-551-3812 or Al Pavot at 202-551-3738
if you have
questions regarding comments on the financial statements and related matters.
Please contact
Kasey Robinson at 202-551-5880 or Christopher Edwards at 202-551-6761 with any

FirstName LastNameTimothy Noyes
                                                           Division of
Corporation Finance
Comapany NameAerovate Therapeutics, Inc.
                                                           Office of Life
June 21, 2021 Page 2
cc:       Edwin O   Connor, Esq.
FirstName LastName